- Home
- Weight Management & Metabolism
- Orforglipron
Weight Management
Orforglipron
Orforglipron · Oral small-molecule GLP‑1 receptor agonist
An oral, non-peptide GLP‑1 receptor agonist. Not a peptide.
- Partner pharmacy
- Personal assistance
- Discreet delivery
Shipping & Delivery
- Normally dispatched within 24 hours of payment confirmation.
- UPS Express · $16 · Approx. 7–9 business days
- Registered Mail · $10 · Approx. 14–20 business days
What is known so far
Orforglipron is an oral small-molecule (non-peptide) GLP‑1 receptor agonist developed for obesity and type 2 diabetes.
Its authorization status in the United States is under review. This page is informational only and does not describe proven clinical benefits.
Product information
Patient information leafletNot available: authorization status under review
Prescribing InformationNot available: authorization status under review
Sources
- US Food and Drug Administration. Novel Drug Approvals for 2026: Foundayo (orforglipron), April 1, 2026.
Related
Weight Management 
